Corbynomics really does make business go up in smoke! Labour leader son’s ‘National Hemp Service’ selling cannabis products goes bust owing £100,000
- Jeremy Corbyn’s son Tommy set up a company selling products made of hemp
- The firm, which was set up with Mr Corbyn’s help, has gone into liquidation
- The Islington-based company was called National Hemp Service – or NHS
- One angry investor claims he has lost £30,000 in the failed start-up venture
23 November 2019
Has Jeremy Corbyn’s son provided a glimpse of the economic future under Labour?
The Daily Mail can disclose that the company Tommy set up with the support of his father has gone into liquidation with debts of £100,000.
For complete Stoner Story go to https://www.dailymail.co.uk/news/article-7716123/Jeremy-Corbyns-sons-firm-goes-liquidation-owing-100-000.html
Legalisation of cannabis IS a fool’s crusade
By Kathy Gyngell November 28, 2019
ON Monday, Times commentator Clare Foges wrote an admirable rebuttal to the LibDems’ much-vaunted cannabis legalisation policy, and took the whole legalisation case by the horns.
Though the self-confessed dope smoker Jo Swinson is unlikely to become PM, Foges points out that she could become a power broker. She has a point – if the LibDems are addicted to anything, it is to their defining but barmy idea that normalising drug use will make it OK. We are also, as Foges sets out in her article, ‘drifting on the tides of fashion towards a dangerous destination’. Debunking the legalisers’ brave new world of dope was never more urgent.
It’s not just political pressure but commercial too. And they are prepared to spend money to get their way. Earlier this year I attended a conference The Spectator hosted for commercial cannabis hopefuls and political lobbyists which was misleadingly subtitled ‘Understanding the impact’. Forget that – there wasn’t a dissenting voice on the platform. It was all about when and why, little about why not. But for Peter Hitchens and David Raynes in the audience no hard questions about the social and health impact of Big Dope would have been posed. For a window into the world of the alternative ‘health’ entrepreneurs and city analysts who can’t wait to exploit this drug and whose attitude is ‘I’m all right, Jack’, this was chilling.
Foges also tackled the perception that to be against legalisation is to be in favour of the status quo. There are few of us however who are satisfied with its blind eye default.
She dealt with the standard arguments against legalisation explaining that ‘losing’ the war on crime doesn’t mean we stop prosecuting it. She reaffirmed too that potency is higher than ever before; that study after study has found a clear association between the high levels of THC which most present-day cannabis contains and serious mental health problems, particularly schizophrenia and psychosis.
But she went further, highlighting hospitalisations and how ‘those tormented by devils today tend to seek sanctuary in the local A&E, where admissions for psychosis have been rising’. An omission in this otherwise tour de force was any mention of the gulag of over-subscribed secure mental health units. Psychiatrists have called them cannabis dependency units, and they are populated largely by irreversibly damaged young male psychotics, betraying the fact that this is not an equal opportunities illness. Young men are the main victims of cannabis. Importantly she did turn to what Peter Hitchens has made his personal crusade which is to report and question ‘the third link in the chain: cannabis use; mental health problems; violent crime’.
Most journalists have carefully avoided the unpalatable (to drug liberalisers) fact of the extraordinary number of brutal crimes in which the assailant had a history of heavy use. Not so Clare Foges.
Many have been documented on a website called Attacker Smoked Cannabis to which Foges refers and whose curator says: ‘Once one learns the characteristics of violence committed by cannabis smokers — frenzied, savage, sustained, unprovoked – such violence becomes easy to spot. A young father violently killing his child? A victim stabbed ten, 20, 50, 100 times? . . . Such crimes used to be rare in the UK and Ireland, if they happened at all. In 2019, there were more than two dozen before Easter.’
She highlights, too, a book called Tell Your Children: The Truth About Marijuana, Mental Illness, and Violence by the former New York Times journalist Alex Berenson which ‘shines a light on the data in states that have legalised cannabis’. The author, she reports, ‘calculated a 35 per cent rise in murders from 2013 to 2017 compared with a 20 per cent rise nationally’ in the four states that changed their laws from 2014 to 2015: Alaska, Colorado, Oregon and Washington.
Foges’s article was one of the most comprehensive reviews of the impact of cannabis liberalisation by a journalist in recent years. Her conclusion, after weighing the evidence, that legalisation is no liberation but the reverse, was hugely welcome, as I wrote to the Times in response.
For those readers not behind the paywall, I wrote:
‘Clare Foges’s warning against the momentum building for cannabis legalisation is timely and welcome. The flawed thinking behind the Lib Dem proposal needs spelling out. Most fundamental is the deceit that cannabis “harms” have derived from its prohibition, not its use. The reverse is the case. ….For more https://www.conservativewoman.co.uk/legalisation-of-cannabis-is-fools-crusade/
California Cannabis Industry Sending SOS To State Leaders As Black Market Continues To Thrive
CBS Sacramento November 28, 2019
“They didn’t realize how strong this illicit market was going to stay,” Hunter said. “I think people really thought that it was just going to stop [after legalization]. And actually, the opposite has happened. It almost feels like the illicit market is getting stronger.
And as 2019 comes to a close, California is indeed home to the world’s largest cannabis market, totaling close to $12 billion in estimated sales. But here’s the rub: $8.7 billion of that is changing hands in the illicit market.
Now, members of California’s cannabis industry are sending an S.O.S. to the state capitol, saying they’re struggling to compete against black market operators who don’t have to meet stringent regulations or pay taxes and fees. They’re urging leaders to make swift regulatory changes or risk the collapse of their emerging industry.
“The hard truth is that until legislative changes are made, our industry will continue to wither away,” said Michael Steinmetz, CEO of cannabis distributor Flow Kana, which recently joined a growing list of California cannabis firms that have cut their workforces.
Following the job cuts, which were first reported by the Sacramento Bee and described as an an “epidemic” of layoffs, Steinmetz cobbled together an informal coalition of more than a dozen leading companies and business associations to lobby the state.
However, not all legacy businesses transitioned to licensed operations under the new laws. While some have no intention to become regulated, others believe it’s cost-prohibitive or currently operate in municipalities where cannabis sales are banned, said Josh Drayton, spokesperson for the California Cannabis Industry Association.
Fewer than 40% of California’s municipalities have cannabis regulations in place, and only one in four of those allow for regulated retail operations, Drayton said. Earlier this year, lawmakers struck down a bill that would have required municipalities to allow recreational cannabis programs if a majority of their residents voted for the 2016 measure that legalized cannabis.
“They didn’t realize how strong this illicit market was going to stay,” Hunter said. “I think people really thought that it was just going to stop [after legalization]. And actually, the opposite has happened. It almost feels like the illicit market is getting stronger.
FDA Says Most CBD Products May Not Be Safe, and Warns 15 Companies to Stop Selling Them
CBD may pose unknown health risks and cannot be marketed as a dietary supplement, food or therapeutic cure-all.
CBD products may be trendy, but health officials are worried that these products — which are often marketed illegally — may not be safe.
Yesterday (Nov. 26), the U.S. Food and Drug Administration (FDA) issued warning letters to 15 companies that sell CBD products because the products violate federal law. The agency also issued an update to consumers about the popular products, and stressed that there is limited evidence for their safety.
CBD, short for cannabidiol, is a chemical found in cannabis that does not induce a mind-bending high. Although drug developers have long sought to uncover the potential health benefits of CBD, to date, only one CBD product has survived the FDA approval process — a prescription drug to treat rare forms of childhood epilepsy. Nonetheless, consumers can now purchase any number of unapproved CBD products, from oils to chocolate bars to pet foods, from companies that claim their goods deliver therapeutic benefits or help treat disease.
These companies have broken federal law by marketing the unproven health benefits of their CBD products, mixing the drug into food, or advertising CBD as a dietary supplement, the FDA announced yesterday. What’s more, these companies may have placed their customers at unknown risk, the FDA said.
“We remain concerned that some people wrongly think that the myriad of CBD products on the market, many of which are illegal, have been evaluated by the FDA and determined to be safe, or that trying CBD ‘can’t hurt,'” Dr. Amy Abernethy, the FDA’s principal deputy commissioner, said in a statement. In reality, the FDA does not have enough data to say whether CBD can be “generally recognized as safe,” and several reports raise questions about the unintended health consequences of consuming the compound.
For instance, when scientists first tested the safety of the approved CBD epilepsy drug, they noted that CBD could inflict damage to the liver. If taken without medical supervision, the damage could prove more extensive, the FDA said in a consumer update on cannabis-derived compounds. Several studies indicate that CBD may alter how the body breaks down other drugs, either increasing or decreasing their potency. In addition, studies in animals suggest the compound may impede the function of testes and sperm, deplete testosterone levels and impair male sexual behavior.
Some reports have uncovered contaminants “such as pesticides and heavy metals” in CBD products, the FDA said. Other studies highlight the potential side effects of taking the compound, including sleep disruption, diarrhea, abdominal pain and mood changes. And questions still linger about how repeated CBD exposure might affect someone over time.
Moreover, the compound may trigger unknown effects in vulnerable populations, including pregnant people and children. Some of the companies called out today specifically market products “for infants and children,” who may not metabolize and excrete the drug as adults do, the agency noted.
“As we work quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD, we’ll continue to monitor the marketplace and take action as needed against companies that violate the law in ways that raise a variety of public health concerns,” Abernethy said.
The FDA defines a “drug” as any non-food product intended to treat a disease, have a therapeutic use, or affect the structure or function of the body. By this definition, many CBD products count as drugs and should be subject to the same scrutiny as other pharmaceuticals, Abernethy said. In addition, the FDA will continue to evaluate the safety and regulation of CBD products intended for “non-drug uses,” according to the consumer update.
“This overarching approach regarding CBD is the same as the FDA would take for any other substance that we regulate,” Abernethy said. The agency encouraged consumers to speak with health care professionals about how to treat diseases and conditions with existing drugs, and to be wary of “unsubstantiated claims” associated with CBD products.
The FDA requested that the companies issued letters respond within 15 working days and report how they plan to correct the violations.
For complete story Originally published on Live Science.
The peer-reviewed journal JAMA Network Open asked Robert L. DuPont, MD and Caroline DuPont, MD, President and Vice President, respectively, of IBH, to respond to a new research study by Bertha K. Madras, et al., “Associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse.”
In their commentary, Drs. DuPont note that this study showed that when parents used marijuana, their children had increased risk of using marijuana too. “This underscores the need for engagement by both parents and health care professionals in youth substance use prevention and parental substance use disorder treatment.” Drs. DuPont then connect the findings to IBH’s own youth prevention work:
The association of parent use of marijuana with offspring use of marijuana and tobacco complements a recent finding suggesting that there is a common liability for substance use among adolescents. Among young people aged 12 to 17 years, the use of one substance is positively associated with the use of others, and nonuse of any one substance is positively associated with non-use of others. There is also evidence that there is a large and steadily increasing number of American youth who do not use any substances, including alcohol, tobacco, or marijuana. More than half (52%) of high school seniors have not used any substance in the past month and more than one-quarter (26%) have not used any substance in their lifetime, up from lows in 1982 of 16% and 3%, respectively. Together, these facts can empower parents when they are educated about their own substance use choices affecting the risks of their children using substances. They can also inform health care professionals that no use of alcohol, nicotine, marijuana, or other drugs is not only the health standard for youth but that nonuse by young patients is common and achievable.
This commentary extends the work of IBH to set a new health standard for youth prevention of One Choice: no use of any alcohol, nicotine, marijuana or other drugs by youth under age 21. Drs. DuPont and the IBH team thank Madras, et al. for their important contribution in JAMA Network Open and thank the journal for the opportunity to share their insights on its implications for prevention and treatment.
A Renewed Focus on Youth Substance Use Prevention Is Needed Among Health Care Professionals and Families
JAMA Netw Open. 2019;2(11):e1916058. doi:10.1001/jamanetworkopen.2019.16058
Using nationally representative data from the National Surveys on Drug Use and Health, the study by Madras et al1 found that parental use of marijuana was associated with the use of marijuana and tobacco by offspring aged 12 to 30 living in the same household.1 The adjusted risks of substance use were up to 2.5-fold higher among offspring of parents who had any lifetime marijuana use compared with their peers whose parents never used marijuana. This study’s demonstration of the associations of intergenerational substance use has important implications for both drug use prevention and addiction treatment.
It is widely known among addiction professionals that most adults with substance use disorders initiated their substance use early in life, before age 18 years,2 a period of rapid development when the brain is uniquely vulnerable to substance use. This underscores the importance for health care professionals, particularly those in family medicine, pediatrics, and adolescent medicine, to address substance use among their patients, keeping in mind the added risk to youth from parental substance use. A first step is to use validated risk tools (eg, Screening to Brief Intervention5 and Brief Screener for Tobacco, Alcohol, and Other Drugs6) to screen young patients for substance use. Not only does screening provide opportunities for early intervention with young patients to prevent the development of subsequent substance use disorders, it also provides opportunities to educate parents about the potential effects of their own behaviors on youth substance use. Parents may question their ability to mitigate or significantly reduce the risks of their children having future substance use disorders; this study by Madras et al1 highlights the fact that their own substance use may increase the risk of their children using these substances.
The association of parent use of marijuana with offspring use of marijuana and tobacco complements a recent finding suggesting that there is a common liability for substance use among adolescents.3 Among young people aged 12 to 17 years, the use of one substance is positively associated with the use of others, and nonuse of any one substance is positively associated with nonuse of others. There is also evidence that there is a large and steadily increasing number of American youth who do not use any substances, including alcohol, tobacco, or marijuana.4 More than half (52%) of high school seniors have not used any substance in the past month and more than one-quarter (26%) have not used any substance in their lifetime, up from lows in 1982 of 16% and 3%, respectively.4 Together, these facts can empower parents when they are educated about their own substance use choices affecting the risks of their children using substances. They can also inform health care professionals that no use of alcohol, nicotine, marijuana, or other drugs is not only the health standard for youth but that nonuse by young patients is common and achievable.
In the area of addiction treatment, the findings in the study by Madras et al1 should motivate treatment professionals to engage families in the addiction treatment process to stop the cycle of substance use disorders within families, recognizing the important association between parent and child substance use. This information could also motivate parents to initiate and maintain treatment for substance use disorders. In our clinical practice, we often see not only that substance use is contagious within families, but so is non-use. Children of adult patients with substance use disorders frequently encourage successful efforts of their parents to become drug free.
Although Madras et al1 could not determine whether the substance use reported by parents or offspring in the study was problematic or what the views were of one another’s substance use, this study shows that when parents use marijuana, their children had increased risk of using marijuana too. This underscores the need for engagement by both parents and health care professionals in youth substance use prevention and parental substance use disorder treatment. Rather than drug-specific approaches to policy, prevention, and treatment, we must recognize the close connection of all substance use as well as the intergenerational contagion of substance use.
For complete article go to https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2755860
Now we are learning that men who want to have healthy babies should not use drugs and alcohol from a biological standpoint as well. A new study, soon to be published by the Boston University School of Public Health and reported on in U.S. News, suggests that men who use marijuana while trying to conceive are more likely to conceive a fetus that miscarries, as opposed to prospective fathers who do not use marijuana at all.
Men who use marijuana at least once a week are twice as likely to see their partner’s pregnancy end in miscarriage, compared to those who use no pot, new research suggests.
Miscarriages related to frequent male pot use tended to occur within eight weeks of conception, which bolsters suspicions that marijuana use damages sperm in some essential way, said lead researcher Alyssa Harlow, a doctoral student at the Boston University School of Public Health.
Some previous studies have indicated that pot use can lower sperm count and reduce the active movement of sperm, Harlow noted. There’s also a possibility that marijuana could cause DNA damage in sperm.
“We would expect that the sperm was healthy enough to fertilize an egg, but any damage to the sperm might result in early pregnancy loss,” Harlow said.
For the study, Harlow and her colleagues gathered data from more than 1,400 couples in the United States and Canada who were trying to conceive.
Men were asked about their pot use — whether they used marijuana less than once a week on average, once or more a week, or never. About 8% of the men said they used pot at least weekly, compared with over 82% who said they never use it.
Nearly 19% of couples who did conceive wound up reporting a miscarriage, the Boston University researchers said.
The association between frequent pot use before conception and miscarriage persisted even after researchers restricted their analysis to couples in which the female partner didn’t use marijuana. Those couples also had a doubled risk of miscarriage if the man used pot at least once a week.
The researchers controlled for a number of factors that could influence risk of miscarriage, including smoking status, alcohol and caffeine intake, weight, amount of sleep, history of sexually transmitted infections, and mood disorders.
That said, only an association was seen in this study, and Harlow noted that there may be other factors associated with either marijuana use or miscarriage that weren’t taken into account.
“More research is needed,” Harlow said.
Mitch Earleywine, an advisory board member of NORML, the pro-marijuana nonprofit organization, agreed that this study cannot prove a direct cause-and-effect link.
While the researchers did a “stellar job” of accounting for other factors that can increase miscarriage risk, he said, “We should keep in mind that marijuana use was not assigned at random here.” Earleywine is a professor of psychology with the State University of New York at Albany.
Although more study is needed, fertility expert Dr. Taraneh Nazem also thinks that “we should be counseling male patients about these preliminary findings.” She is an assistant clinical professor of obstetrics, gynecology and reproductive science with the Icahn School of Medicine at Mount Sinai in New York City.
“I think we have enough evidence to suggest there is a potential negative impact from marijuana use on male fertility,” said Nazem. “If a male patient is trying to conceive with his partner, I would counsel him to make some lifestyle modifications based on this preliminary data.”
“The millions of regular marijuana users who have successfully sired children with ease will balk at the idea, but those couples who’ve endured this outcome can certainly consider decreasing frequency of use for a few months in an effort to have children,” Earleywine said.
The study was to be presented Monday at the annual meeting of the American Society for Reproductive Medicine, in Philadelphia. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.
H. Baker – Drug Free Australia
Cannabis-induced psychosis blamed in beheading of father at Muskoka cottage
Warning: Graphic and disturbing content
The court heard cannabis-induced psychosis, not a major mental disorder, spurred the brutal death of 67-year-old John Kehl by his then 31-year-old son Adam.
Adam Kehl voluntarily entered a plea of guilty to manslaughter in front of The Honourable Michelle Fuest in Barrie court on Nov. 22 who called the incident “horrifying and unusually brutal.”
The following (not publicly reported) heinous drug-induced behaviour happened in Pueblo, Colorado earlier November 2019
A young man who used a cannabis wax and then experienced an excited delirium episode in which he ran in on coming traffic swinging a metal rod at cars. He was tazed and tackled by police and came in with 3 police officers and 5 paramedics working to hold him down. Prior to arrival EMS had given him 50 mg of diphenhydramine, 5 mg of Haldol, and 2 mg of Versed and he continued to be that combative. On arrival here he took all of the aforementioned personnel plus 3 of our security officers to hold and move him to the bed and hold him down. I gave 10 mg of Versed with plans to likely need to intubate him. He became more relaxed and calm following, never required intubation. UDS only positive for cannabis. He developed rhabdo and was admitted to the peds service for this following.
Patient was 17 years old
“High potency” is typically 10-12% THC. That simply does not exist in Colorado. It’s too weak. Our kids have access to 17-20% THC easily to smoke as well as concentrates pushing 40-60% THC as well as the wax/shatters which are 90%+ THC. Easily and readily available to adolescents in Colorado.
We are at a tipping point in the US with our kids using these products.
Colorado Medical Doctor
What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD
The FDA is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.
- The FDA has approved only one CBD product, a prescription drug product to treat two rare, severe forms of epilepsy.
- It is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.
- The FDA has seen only limited data about CBD safety and these data point to real risks that need to be considered before taking CBD for any reason.
- Some CBD products are being marketed with unproven medical claims and are of unknown quality.
- The FDA will continue to update the public as it learns more about CBD.
- CBD has the potential to harm you, and harm can happen even before you become aware of it.
- CBD can cause liver injury.
- CBD can affect the metabolism of other drugs, causing serious side effects.
- Use of CBD with alcohol or other Central Nervous System depressants increases the risk of sedation and drowsiness, which can lead to injuries.
- CBD can cause side effects that you might notice. These side effects should improve when CBD is stopped or when the amount ingested is reduced.
- Changes in alertness, most commonly experienced as somnolence (drowsiness or sleepiness).
- Gastrointestinal distress, most commonly experienced as diarrhea and/or decreased appetite.
- Changes in mood, most commonly experienced as irritability and agitation.
- There are many important aspects about CBD that we just don’t know, such as:
- What happens if you take CBD daily for sustained periods of time?
- What is the effect of CBD on the developing brain (such as children who take CBD)?
- What are the effects of CBD on the developing fetus or breastfed newborn?
- How does CBD interact with herbs and botanicals?
- Does CBD cause male reproductive toxicity in humans, as has been reported in studies of animals?
For more go to FDA Consumer Updates: Cannabis
For Immediate Release:
November 25th, 2019
SAM Applauds HHS for Blocking Opioid Grant Funds from Medical Marijuana Programs
(Alexandria, VA) – The Substance Abuse and Mental Health Services Administration (SAMHSA) announced on Friday that federal monies doled out by the health agency would no longer flow to individuals or organizations that use, prescribe, or provide marijuana for the treatment of opioid use disorder and mental health issues. Furthermore, SAMHSA Director Elinore McCance-Katz stated that treatment programs must document efforts urging patients to stop using marijuana to prevent a loss of federal funding.
“We commend the Department of Health and Human Services for this decision, which will have a significant positive impact on public health,” said Dr. Kevin Sabet, president of Smart Approaches to Marijuana and a former senior drug policy advisor to the Obama Administration. “Numerous studies have been released in the last year alone showing that marijuana use has no positive impact on opioid addiction. It is refreshing to see SAMHSA take such a firm action against the misinformation campaign being peddled on this front by the marijuana industry.”
Claiming marijuana could be a solution to the opioid epidemic has been a key talking point for the marijuana industry in its efforts to legalize the drug. Legalization supporters have covered states considering legalization in billboards promoting a 2014 study claiming states that legalized marijuana experienced a 25 percent reduction in opioid deaths. This year, Stanford researchers attempted to recreate the 2014 study and instead found legalization resulted in a 25 percent increase in opioid deaths.
Just last week, Canadian researchers at McMaster University analyzed twenty-three studies with more than 3,600 participants and found that marijuana use neither led to reduced opioid use during treatment, nor did it lead to people staying in treatment programs.
In October, a study by researchers in Oregon and California found 78 percent of states where marijuana was “legal” significantly higher rates of opioid-related deaths after legalization than states that have not legalized the drug. Furthermore, a study published earlier this year in Substance Use and Addiction, a JAMA-related publication, concluded that “medical marijuana law enactment was not associated with a reduction in individual-level non-medical opioid abuse, contradicting the hypothesis that people would substitute marijuana for prescription opioids.”
Furthermore, researchers from the National Institutes of Health found that marijuana users are 2.6 times more likely than nonusers to abuse opioids and develop an opioid addiction.
“For far too long, we have allowed the marijuana industry to play fast and loose with the science while ignoring warnings from the medical and scientific communities,” continued Dr. Sabet. “Assistant Secretary McCance-Katz and SAMHSA are to be applauded for beginning a much-needed pushback against the dangerous myths being perpetuated by the marijuana industry.”
Smart Approaches to Marijuana (SAM) is the nation’s leading nonpartisan, non-profit public health alliance of concerned citizens and professionals who oppose marijuana legalization and support science-backed marijuana policies. SAM and its 30+ state affiliates have successfully prevented marijuana legalization in dozens of state legislatures and at the ballot box.
Guided by a Scientific Advisory Board of scientists from Harvard, Princeton, and University of Colorado, SAM educates the public on cutting edge science: marijuana is harmful, addictive, and legalization creates social injustice and expands illicit market activity.
For more information about marijuana use and its effects, visit www.learnaboutsam.org.